Why GeneDx Holdings Stock Is Plunging Today

Shares of GeneDx Holdings (NASDAQ: WGS) were plunging 42.9% as of 11:21 a.m. ET on Wednesday. The steep decline came after the genetic diagnostics company announced its 2025 first-quarter earnings before the market opened.

GeneDx reported Q1 revenue of $87.1 million, up 42% year over year. This result was well above the consensus Wall Street forecast of $79.5 million.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

What about GeneDx's bottom line? The company posted a Q1 net loss of $6.5 million based on generally accepted accounting principles (GAAP). However, its adjusted net earnings for the quarter were $7.7 million, or $0.27 per share. The average analysts' estimate projected adjusted earnings per share of $0.09.

What were the concerns with GeneDx's Q1 update?

It's unusual for a stock to decline as much as GeneDx has today after topping Wall Street's revenue and earnings estimates. So what were the concerns with the company's Q1 update?

For one thing, investors have become accustomed to GeneDx beating revenue estimates by a much wider margin in the past. A revenue beat of less than 10% was likely disappointing to many. Also, GeneDx's test volume declined quarter over quarter for the first time since the company's initial public offering in 2020.

Is GeneDx stock a buy on the sell-off?

Today's sell-off appears to be overdone. GeneDx's Q1 year-over-year comparisons suffered because this Q1 had one fewer business day than the prior-year period. Importantly, the company raised its full-year revenue guidance to between $360 million and $375 million from the previous range of $350 million to $360 million.

The upper end of GeneDx's revenue outlook reflects a forward price-to-sales ratio of roughly 5.4. This looks expensive relative to the life sciences tools and services industry's forward multiple of around 4.8. Some aggressive investors might find GeneDx stock appealing after the big plunge. However, I think other stocks offer a better risk-reward proposition.

Should you invest $1,000 in GeneDx right now?

Before you buy stock in GeneDx, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and GeneDx wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $607,048!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $668,193!*

Now, it’s worth noting Stock Advisor’s total average return is 880% — a market-crushing outperformance compared to 161% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of April 28, 2025

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.